Gastrointestinal and Hepatic Manifestations of Chronic Granulomatous Disease.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
05 2023
Historique:
received: 08 07 2022
revised: 02 12 2022
accepted: 20 12 2022
medline: 9 5 2023
pubmed: 17 1 2023
entrez: 16 1 2023
Statut: ppublish

Résumé

Chronic granulomatous disease (CGD) is a rare inborn error of immunity, resulting from a defect in nicotinamide adenine dinucleotide phosphate oxidation and decreased production of phagocyte reactive oxygen species. The main clinical manifestations are recurrent infections and chronic inflammatory disorders. Current approaches to management include antimicrobial prophylaxis and control of inflammatory complications. Hematopoietic stem cell transplantation or gene therapy can provide definitive treatment. Gastrointestinal and hepatic manifestations are common in CGD and include structural changes, dysmotility, CGD-associated inflammatory bowel disease, liver abscesses, and noncirrhotic portal hypertension. The findings can be heterogeneous, and the management is complex in light of the underlying immune dysfunction. This review describes the various clinical findings and the latest studies in management of gastrointestinal and hepatic manifestations in CGD, as well as the management experience at the National Institutes of Health.

Identifiants

pubmed: 36646382
pii: S2213-2198(23)00050-8
doi: 10.1016/j.jaip.2022.12.039
pii:
doi:

Substances chimiques

NADPH Oxidases EC 1.6.3.-

Types de publication

Review Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1401-1416

Informations de copyright

Published by Elsevier Inc.

Auteurs

Alexander H Yang (AH)

Digestive Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md.

Brigit Sullivan (B)

Office of the Director, National Institutes of Health, Bethesda, Md.

Christa S Zerbe (CS)

Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Suk See De Ravin (SS)

Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Andrew M Blakely (AM)

Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Martha M Quezado (MM)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Beatriz E Marciano (BE)

Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Jamie Marko (J)

Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md.

Alexander Ling (A)

Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Md.

David E Kleiner (DE)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Md.

John I Gallin (JI)

Clinical Pathophysiology Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Harry L Malech (HL)

Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Steven M Holland (SM)

Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Theo Heller (T)

Translational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md. Electronic address: theoh@intra.niddk.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH